Back to Freepaper Session

Intraoperative aberrometry-guided toric IOL alignment

Session Details

Session Title: Intraoperative Biometry and Correction of Astigmatism

Session Date/Time: Monday 07/10/2013 | 08:00-10:00

Paper Time: 08:29

Venue: Main Lecture Hall (Ground Floor)

First Author: : K.Heiberger GERMANY

Co Author(s): :    T. Neuhann              

Abstract Details

Purpose:

The postoperative outcome of toric and multifocal IOLs is largely determined by (a) the accuracy of the biometry and the selection of the ideal IOL, (b) the reliability of the keratometry measurements, (c) the precision of marking the target axis and the visibility of the ink markings during the surgery, and (d) the precision of the intraocular alignment of the IOL.

Setting:

AaM Augenklinik am Marienplatz Munich, Germany

Methods:

Ten consecutive implantations of toric IOLs were included in this first clinical study. The measurements on the aphakic eyes were compared with the position of the ink marks and the preop measurements. In addition, we compare the intraop measurements of the resulting refraction with the postop measurements. The refraction data from the intraoperative wavefront analyzer and the position of the ink marks were recorded on video streams and taken in Excel to calculate the deviations.

Results:

The intraoperative use of this new sensor technology seems to work very reliably. The visualization of the cross-hairs in the surgical microscope makes a highly precise positioning possible. Ink marks can diffuse or disappear during surgery. The virtual axis marking can always be displayed in the microscope.

Conclusions:

After the ongoing technical development of the capabilities and reliability of the pre- and post-operative diagnosis in the last 20 years, we are currently experiencing a rapid development in intraoperative aberrometry. In particular, the possibilities of intraoperative ocular wavefront aberrometry in real-time is very promising. More experience and further research are necessary to validate the reliability, accuracy and clinical benefits of this new approach.

Financial Interest:

NONE